Called BJI InoPlex, the kit detects approximately 75 % cent of infections found in joint replacements. It uses several recombinant protein antigens to enable users to carry out key tasks in diagnosing and treating these infections. This includes confirming or eliminating an infection from among bacterial groups that are most commonly found in bone and joint infections (Staphylococcus), assessing the potential for infection by detecting the patient's immunoreaction, and enabling the biological monitoring of antibiotic treatment in patients.

Ingen Biosciences (Chilly-Mazarin, France), a developer and marketer of advanced in vitro diagnostic kits for clinical use, announced that the company will market BJI InoPlex in Europe. The kit consists of a panel of new high-standard antigens developed by the company.

The alternative to Ingen Biosciences' noninvasive serological test is to put patients through a lengthy and costly surgical procedure to open up the knee joint, for example, and search for the infection. BJI InoPlex offers major economic benefits in detecting, treating, and monitoring infection in the joint replacement process.

Through a standard industry technology license, Ingen Biosciences has the rights to sell the kit in Europe. The company plans to sell to other geographic markets in the future. The company also plans to launch a second-generation diagnostics kit in 2011 that will include new antigens to detect other infections in joint replacements.

The Ingen Biosciences Group develops and markets advanced in vitro diagnostic kits for clinical use. Its primary focus is on infectious diseases and immunology, including HLA testing.

Related Links:
Ingen Biosciences